Health Affairs, 25, no. 5 (2006): 1291-1301 doi: 10.1377/hlthaff.25.5.1291 © 2006 by Project HOPE	New Online   Pay Cuts For Medicare Docs   Access To Care Woes   Public Coverage More Efficient   Empowering Consumers

This Article Full Text (HTML) Reprint (PDF) Online Appendix Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Grabowski, H. Articles by Long, G. Search for Related Content PubMed PubMed Citation Articles by Grabowski, H. Articles by Long, G. Related Collections Insurance Market Access To Care Business Of Health Consumer Issues Evidence-Based Medicine Insurance Coverage Managed Care - Medicare Medicare Pharmaceuticals Research And Technology Health Spending

Evolution & Future

The Market For Follow-On Biologics: How Will It Evolve?

With spending on biologics rising and patent expiry approaching for several blockbuster biologics, Congress and the Food and Drug Administration are considering creating a clear pathway for so-called follow-on biologics. Differences between drugs and biologics will affect market outcomes in various ways. Conservative budget impacts are appropriate in the short run because fewer competitors will enter, and average prices will drop less than was the case following the Hatch-Waxman Act. Over the long term, intellectual property provisions will be important considerations for policymakers designing a pathway for follow-on biologics that balances price competition and innovation incentives.

                      What's this?

This article has been cited by other articles:

				D. M. Dudzinski and A. S. Kesselheim Scientific and Legal Viability of Follow-on Protein Drugs N. Engl. J. Med., February 21, 2008; 358(8): 843 - 849. [Full Text] [PDF]

				J. M. Hoffman, N. D. Shah, L. C. Vermeulen, G. T. Schumock, P. Grim, R. J. Hunkler, and K. M. Hontz Projecting future drug expenditures--2007 Am. J. Health Syst. Pharm., February 1, 2007; 64(3): 298 - 314. [Abstract] [Full Text] [PDF]